Sai Parenterals Limited has announced the launch of its Initial Public Offering (IPO) on March 24, 2025.79 crore, will remain open for public subscription until March 27, 2025. The company has fixed the price band for the offering at ₹372 to ₹392 per equity share. Anchor investors will have the opportunity to place their bids on March 23, one day prior to the public opening.
IPO Structure and Key Timeline
79 crore. Under the OFS, several existing shareholders, including Vikasa India EIF I Fund, Tilokchand Poonamchand Ostwal, Devendra Chawla, Ashish Maheshwari, Padma Guntupalli, Bhautik Mukund Shah, and Nilesh Pravinchandra Doshi, will divest their holdings. The basis of allotment is expected to be finalized by March 30, with the shares likely to debut on the BSE and NSE on April 2, 2025. The minimum lot size for retail investors is set at 38 shares.
Business Operations and Product Portfolio
Sai Parenterals is a diversified pharmaceutical formulations company specializing in research, development, and manufacturing. The company operates through two primary business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for both domestic and international markets. Its extensive product portfolio covers multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, analgesics, dermatology, and Vitamins, Minerals, and Supplements (VMS).
Manufacturing Capabilities and Market Reach
The company offers its products in various dosage forms, such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenterals currently operates five manufacturing facilities across India. Its clientele includes central and state government agencies, major pharmaceutical companies, public and private hospitals, and super stockists. Beyond the Indian market, the company exports its products to several international regions, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Utilization of IPO Proceeds
The net proceeds from the fresh issue of ₹285 crore are earmarked for several strategic initiatives. 80 crore will be utilized for expanding and upgrading the capacity of existing manufacturing plants. 02 crore is allocated for the establishment of a new Research and Development (R&D) center. 30 crore will be used for the repayment of certain outstanding borrowings, while ₹33 crore is set aside for working capital requirements. 64 crore in its subsidiary, Sai Parenterals Pte Limited in Singapore, with the remaining funds intended for general corporate purposes.
Financial Performance and Management
43 crore. 76 crore. The company is promoted by Anil Kumar Karusala, Vijitha Gorepati, and Karusala Aruna. Arihant Capital Markets Limited is serving as the book-running lead manager for the IPO, while Bigshare Services Private Limited has been appointed as the registrar to the issue.